- Condition: Alzheimer's Disease
Interventions: Drug: E2609; Drug: Placebo
Sponsors: Eisai Inc.; Eisai Inc.
Not yet recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: PLX3397; Drug: Eribulin
Sponsors: University of California, San Francisco; Hope Rugo, MD; Susan G. Komen Breast Cancer Foundation; Plexxikon, Inc.; Eisai Inc.
Not yet recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Eribulin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eisai Inc.
Not yet recruiting - verified May 2012 - Conditions: Malignant Solid Tumour; Breast Cancer Nos Metastatic Recurrent; Neuropathy
Intervention: Drug: Eribulin in Combination w/ Cyclophosphamide
Sponsors: University of California, San Francisco; University of California, San Francisco; Eisai Inc.
Not yet recruiting - verified March 2012 - Condition: Crohn's Disease
Intervention: Other: Observation study
Sponsors: Kyunghee University Medical Center; Kyunghee University Medical Center; Asan Medical Center; Hanyang university Guri Hospital; Inje University; Seoul National University; Yonsei University; Eisai Korea Inc.; Samsung Medical Center; The Catholic University of Korea; Chung-Ang University
Not yet recruiting - verified March 2012 - Condition: Epilepsy
Interventions: Drug: Zonisamide 25 mg; Drug: Zonisamide 50 mg; Drug: Zonisamide 100 mg; Drug: Placebo
Sponsors: Eisai Inc.; Eisai Limited
Terminated - verified March 2012 - Condition: Alzheimer's Type Dementia
Interventions: Drug: E2020; Drug: E2020
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Recruiting - verified March 2012 - Condition: Central Nervous System
Interventions: Drug: alcohol + placebo; Drug: alcohol + perampanel; Drug: perampanel + alcohol; Drug: placebo + alcohol
Sponsors: Eisai Inc.; Eisai Limited
Completed - verified January 2012 - Condition: Idiopathic Thrombocytopenic Purpura
Interventions: Drug: 10-mg dose of E5501 2G tablet; Drug: 10-mg dose of E5501 cyclodextrin oral solution; Drug: 10-mg dose of E5501-P21% powder; Drug: 10-mg dose of E5501 lipid-based oral
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified March 2012 - Conditions: Refractory Solid Tumors; Lymphomas
Interventions: Drug: E7080; Drug: Moxifloxacin 400 mg; Drug: Placebos (matched to 4 mg and 10 mg E7080 capsules).
Sponsors: Eisai Inc.; Eisai Inc.
Completed - verified April 2012 - Condition: Locally Advanced HER2-Negative Breast Cancer
Interventions: Drug: Eribulin Mesylate; Drug: Cyclophosphamide; Drug: Docetaxel
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Eisai Inc.
Not yet recruiting - verified March 2012 - Condition: Functional Dyspepsia
Interventions: Drug: Rabeprazole and Amoxicillin; Drug: Amoxicillin and Rabeprazole
Sponsors: Shanghai Jiao Tong University School of Medicine; Shanghai Jiao Tong University School of Medicine
Completed - verified January 2012 - Condition: Healthy
Interventions: Drug: E2609; Drug: Placebo
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified May 2012 - Condition: Healthy Adult
Interventions: Drug: Donepezil Hydrochloride; Drug: Donepezil Hydrochloride; Drug: Donepezil Hydrochloride; Drug: Donepezil Hydrochloride
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Completed - verified January 2012 - Condition: Healthy Adult
Interventions: Drug: Donepezil Hydrochloride; Drug: Donepezil Hydrochloride; Drug: Donepezil Hydrochloride
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Completed - verified January 2012 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Lenvatinib (E7080)
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Not yet recruiting - verified March 2012 - Condition: Chronic Chagas Disease, Indeterminate
Interventions: Drug: E1224; Drug: Benznidazole; Drug: Placebo
Sponsors: Drugs for Neglected Diseases; Drugs for Neglected Diseases; Eisai Co., Ltd.
Recruiting - verified December 2011 - Condition: Central Nervous System
Intervention: Drug: perampanel
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified January 2012 - Condition: Atopic Dermatitis
Interventions: Drug: E6005; Drug: E6005 ointment (vehicle)
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Recruiting - verified March 2012 - Condition: Insomnia
Interventions: Drug: E2006 1.0 mg; Drug: E2006 2.5 mg; Drug: E2006 5.0 mg; Drug: E2006 10.0 mg; Drug: E2006 25.0 mg; Drug: E2006 50.0 mg; Drug: E2006 100 mg; Drug: E2006 200 mg; Drug: zolpidem 10 mg; Drug: zolpidem - matched placebo; Drug: E2006 - matched placebo
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Condition: Soft Tissue Sarcoma
Intervention: Drug: E7389
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Recruiting - verified December 2011 - Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Eribulin; Drug: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors; Cancer of the Breast; Neoplasms, Breast; Tumors, Breast
Interventions: Drug: Eribulin; Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: Emory University; Emory University; Eisai Inc.
Recruiting - verified December 2011 - Condition: Healthy
Interventions: Drug: E2022; Drug: Placebo
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Recruiting - verified October 2011 - Condition: Breast Cancer
Intervention: Drug: Eribulin Mesylate
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Recruiting - verified October 2011 - Condition: Idiopathic Thrombocytopenic Purpura (ITP)
Intervention: Drug: E5501
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified November 2011 - Conditions: Chronic Thrombocytopenia; Immune Thrombocytopenia
Intervention: Drug: E5501
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified January 2012 - Conditions: Estrogen Receptor Positive Tumor; Breast Cancer
Intervention: Drug: E7389 (eribulin mesylate) and capecitabine
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Condition: Idiopathic Thrombocytopenic Purpura
Interventions: Drug: Eltrombopag; Drug: E5501
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Drug: E7389
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Recruiting - verified March 2012 - Condition: Advanced Solid Tumors
Interventions: Drug: E7050 plus E7080; Drug: E7080 plus E7050; Drug: E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; Drug: E7050 plus E7080; Drug: E7050
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified March 2012 - Condition: Cancer
Intervention: Drug: Denileukin diftitox (ONTAK)
Sponsors: Eisai Inc.; Eisai Inc.
Available - verified April 2012 - Conditions: Solid Tumor; Gastric Cancer
Intervention: Drug: E7050
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Recruiting - verified January 2012 - Condition: Healthy
Intervention: Drug: Torrent's Donepezil Hydrochloride Tablets 10mg
Sponsors: Torrent Pharmaceuticals Limited; Torrent Pharmaceuticals Limited
Completed - verified August 2011 - Condition: Healthy
Intervention: Drug: Torrent's Donepezil Hydrochloride Tablets 10mg
Sponsors: Torrent Pharmaceuticals Limited; Torrent Pharmaceuticals Limited
Completed - verified August 2011 - Conditions: Sickle Cell Disease; Vaso-occlusive Crisis
Interventions: Drug: Placebo; Drug: Dalteparin
Sponsors: Duke University; Duke University; Eisai Limited
Recruiting - verified August 2011 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: E7389; Drug: E7389; Drug: E7389
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified May 2012 - Condition: Alzheimer's Type Dementia
Interventions: Drug: E2020; Drug: Placebo
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Recruiting - verified February 2012 - Condition: Lennox-Gastaut Syndrome
Interventions: Drug: Rufinamide; Drug: Any other approved AED
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Conditions: Gastric Ulcers; Duodenal Ulcers
Interventions: Drug: E3810; Drug: E3810
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Not yet recruiting - verified October 2011 - Conditions: Gastric Ulcers; Duodenal Ulcers
Interventions: Drug: E3810; Drug: E3810; Drug: Teprenone
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Recruiting - verified October 2011 - Condition: Seizure Disorder Generalized Tonic Clonic
Interventions: Drug: perampanel; Drug: placebo comparator
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified January 2012 - Condition: Healthy
Interventions: Drug: perampanel; Drug: perampanel
Sponsors: Eisai Inc.; Eisai Inc.
Completed - verified April 2012 - Condition: Healthy
Interventions: Drug: Perampanel; Drug: Perampanel
Sponsors: Eisai Inc.; Eisai Inc.
Completed - verified April 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: eribulin mesylate; Drug: eribulin mesylate, trastuzumab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Eisai Inc.
Recruiting - verified March 2012 - Conditions: Enteropathy-Associated T-Cell Lymphoma; Anaplastic Large-Cell Lymphoma; Cutaneous T-Cell Lymphoma; Primary Cutaneous Anaplastic Large Cell Lymphoma; Mycosis Fungoides; Sezary Syndrome; Peripheral T-Cell Lymphoma
Intervention: Biological: denileukin diftitox
Sponsors: TSD Japan Inc.; TSD Japan Inc.; Eisai Co., Ltd.
Recruiting - verified July 2011 - Condition: HER-2 Positive Breast Cancer
Interventions: Drug: eribulin; Drug: carboplatin; Drug: trastuzumab
Sponsors: ACORN Research, LLC; ACORN Research, LLC; Eisai Inc.
Recruiting - verified January 2012 - Condition: Gastroesophageal Reflux Disease
Interventions: Drug: E3710; Drug: E3710
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Completed - verified March 2012 - Conditions: Complication of Injection; Pain
Interventions: Drug: Fospropofol; Drug: Propofol/Lidocaine
Sponsors: New York University School of Medicine; New York University School of Medicine; Eisai Inc.
Recruiting - verified November 2011 - Conditions: Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: carboplatin; Procedure: biopsy
Sponsors: Northwestern University; Northwestern University; Eisai Inc.
Not yet recruiting - verified June 2011


